Search clinical trials for: apatinib

Total 2163 results

Xiangya Hospital of Central South University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Gastrointestinal Stromal Tumors

China
Shandong University
The Affiliated Hospital of Qingdao University; Qianfoshan Hospital; The Second...

Recruiting

Antineoplastic Drugs in Elderly Patients

Cancer

China
University of Florida

Withdrawn

Explore the Synergy of Combination TKI Therapy

Healthy Volunteers
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Baylor College of Medicine

Recruiting

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission | Chronic Myeloid Leukemia in Remission

United States
Bristol-Myers Squibb

Withdrawn

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Myeloid Leukemia, Chronic, Chronic-Phase

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Leukemia

United States
Pusan National University Hospital

Available

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Chronic Myeloid Leukemia
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell Lung

China
Azienda Socio Sanitaria Territoriale degli Spedali...

Recruiting

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Leukemia, Chronic Myeloid

Italy
Boehringer Ingelheim

Completed

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

Breast Neoplasms

United States, Brazil, Colombia, Peru
Mayo Clinic
National Cancer Institute (NCI)

Completed

Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific

United States
University of Liverpool
Imperial College London; Newcastle University; University of Glasgow

Unknown

De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia (DESTINY)

Chronic Myeloid Leukaemia

United Kingdom
University of Auckland, New Zealand
Leukaemia & Blood Cancer New Zealand

Active, not recruiting

KISS Study: Kinase Inhibition With Sprycel Start up (KISS)

Chronic Myeloid Leukemia

New Zealand
Bristol-Myers Squibb

Terminated

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Leukemia, Myeloid, Chronic

Sweden, United Kingdom, Russian Federation, France, Germany, Belgium, Portugal, Finland, Norway, Spain, Italy
Asan Medical Center

Withdrawn

Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML) (IDEAL-E)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Korea, Republic of
Bristol-Myers Squibb

Terminated

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Leukemia

United States
Bristol-Myers Squibb

Completed

Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey

Leukemia, Myeloid, Chronic-Phase (CML-CP)
National Research Center for Hematology, Russia

Active, not recruiting

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) (READIT)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | BCR-ABL Positive Chronic Myelogenous Leukemia

Russian Federation
Norwegian University of Science and Technology

Completed

Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia (NordCML006)

Chronic Myeloid Leukemia

Sweden, Finland, Norway
Newcastle University
Bristol-Myers Squibb; Institute of Cancer Research, United Kingdom; Newcastle-upon-Tyne... and other collaborators

Completed

Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia (SPIRIT2)

Myeloid Leukemia, Chronic, Chronic Phase

United Kingdom
Bristol-Myers Squibb

Completed

A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (DASISION)

Myeloid Leukemia, Chronic

Germany, India, Japan, Korea, Republic of, Turkey, Chile, China, Spain, Australia, France, Poland, Mexico, Colombia, Belgium, Austria, Italy, Peru, Greece, Brazil, Czech Republic, Hungary, Russian Federation, Netherlands, Argentina, Den... and more
Bristol-Myers Squibb
PPD; ICON Clinical Research; Q2 Solutions; Molecular MD; MultiPharma; Steering Committee and other collaborators

Completed

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)

Chronic Phase Chronic Myeloid Leukemia

Italy, Thailand, United States, Belgium, Czechia, Hungary, Argentina, Austria, Brazil, Canada, China, France, Korea, Republic of, Poland, Spain
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Philadelphia-Positive Myeloid Leukemia

Belgium, Spain, United States, Italy, Argentina, Brazil, Canada, Germany, Peru, Puerto Rico, Singapore, South Africa, Taiwan, United Kingdom, Australia, France, Philippines, Sweden, Thailand, Russian Federation, China, Poland, Finland, Isra... and more
Pfizer

Completed

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Chronic Myeloid Leukaemia

Hungary
Bristol-Myers Squibb

Completed

Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (START rollover)

Leukemia

Germany, Italy, Korea, Republic of, Sweden, Thailand, United States, Australia, France, Poland, Switzerland, Spain, Ireland, Peru, Brazil, South Africa, Canada, Argentina, Hungary, Finland, Israel, Norway, Russian Federation, United... and more
Fudan University

Unknown

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Tumor

China
Elevar Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Adenoid Cystic Carcinoma

United States, Korea, Republic of
Shanghai Jiao Tong University Affiliated Sixth...

Unknown

A Phase II Study of Apatinib in STS Patients

Soft Tissue Sarcoma
UNC Lineberger Comprehensive Cancer Center

Completed

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | CML - Philadelphia Chromosome | CML (Chronic Myelogenous Leukemia

United States
Oslo University Hospital
The Research Council of Norway

Completed

N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (MetAction)

Metastatic Cancer

Norway
Peking University Cancer Hospital & Institute

Recruiting

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Acral Melanoma

China
Tianjin Medical University Cancer Institute and...

Unknown

Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer

China
Wuhan Union Hospital, China

Withdrawn

Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer (XHZL)

Colorectal Cancer | Chemotherapy | Angiogenesis
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Treatment of Carrying TP53 Harmful Mutations

Advanced Cancer

China
Masaryk University

Active, not recruiting

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia (HALF)

Chronic Myeloid Leukemia, Chronic Phase | Withdrawal;Drug

Czechia
The First Affiliated Hospital of Zhengzhou University

Recruiting

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Esophageal Cancer by AJCC V8 Stage

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
Lei Li

Completed

First-line Chemotherapy for Recurrent Cervical Cancer

Chemotherapy | Recurrent Cervical Carcinoma | Apatinib | Targeted Therapy | Persistent Advanced Cervical Carcinoma | Vascular Endothelial Growth Factor 2 Inhibitor

China
Peking Union Medical College Hospital

Completed

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)

Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | Biomarker

China
Peking Union Medical College Hospital

Completed

Study of Apatinib in Patients With Differentiated Thyroid Cancer

Thyroid Cancer

China
Huazhong University of Science and Technology

Unknown

Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

Gastric Cancer

China
Ruijin Hospital

Active, not recruiting

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Shoucheng Ma

Unknown

Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients

Colorectal Neoplasms

China
Beijing Hospital
Chinese Society of Clinical Oncology

Recruiting

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

Solid Tumor

China
BioGene Pharmaceutical Ltd.

Withdrawn

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)

Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis Externa

Switzerland
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Metastatic Biliary Tract Cancer | Locally Advanced Biliary Tract Cancer

China
Sun Yat-sen University

Not yet recruiting

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Neoplasia

China

Search clinical trials for: apatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations